| Date | Title | Description |
| 13.01.2025 | Forbion promotes Dirk Kersten to Managing Partner and strengthens US team | • Dirk Kersten promoted to Managing Partner, further strengthening firm’s leadership
• Jonathan McNeill, M.D. joins Forbion as Partner in the Boston office
Naarden, The Netherlands – 13 January 2025 - Forbion, a leading global life sciences... |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 27.06.2024 | Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office | • Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion
• Brumm to be located at Forbion's new offices in the heart of the Boston (MA) biotech hub, supporting Forbion’s long-standing activities in the US a... |
| 28.05.2024 | Dyne Therapeutics Announces Closing of Public Offering of Common Stock & Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases... |
| 22.05.2024 | Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock | WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven disease... |
| 21.05.2024 | Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock | - |
| 05.03.2024 | Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights | - |
| 04.01.2024 | Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock | WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven disease... |
| 04.01.2024 | Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock | - |
| 03.11.2022 | Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights | /EIN News/ -- - DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 -
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage musc... |
| 18.01.2022 | Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy | WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today annou... |
| 02.12.2021 | Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy | - DYNE-251, Dyne’s First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 -
- DYNE-101 IND Submission in DM1 Expected in the First Quarter of 2022 -
- Initiation of Patient Dosing of DYNE-251 and DYNE... |
| 03.04.2021 | Dyne Therapeutics : Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights | - Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -
- Recent Appointments to Experienced Leadership Team Strengthen Company's Clinical Development Capa... |
| 04.03.2021 | DYNE THERAPEUTICS, INC.
Dyne Therapeutics : Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights | - Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -
- Recent Appointments to Experienced Leadership Team Strengthen Company's Clinical Development Capa... |
| 11.08.2020 | DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANCE PIPELINE OF MODERN OLIGONUCLEOTIDE THERAPEUTICS FOR SERIOUS MUSCLE DISEASES | - |
| 10.08.2020 | Dyne Therapeutics Raises $115M in Equity Financing | Dyne Therapeutics, a Waltham, Mass.-based biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, closed a $115m equity financing.
The round was led by new investors Vida Ventures a... |
| 10.08.2020 | Dyne Therapeutics Announces $115M Financing |
WALTHAM, MA, Dyne Therapeutics announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital.
>> Click here for more funding data on Dyne Therapeutics
>> To export Dyne Ther... |
| 10.08.2020 | Dyne Therapeutics Announces $115 Million Financing | WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by n... |
| 10.08.2020 | Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases | - |
| 12.06.2020 | 'Rising star' CEO recounts path from pre-med to breakthrough meds; Dendreon taps Big Pharma vet Jason O'Neill as CEO | Freshman year was a transformative one for Aetna Wun Trombley.
Aetna Wun Trombley
Having enrolled at the University of California, San Diego thinking she would become a pediatrician some day, she got intrigued by the ... |
| 24.04.2020 | Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO | Laura Shawver
Laura Shawver didn’t quite understand cancer until she had it.
By that point, in 2006, she had already been making oncology drugs for over 15 years, a dyed-in-the-wool researcher who had obtained a PhD in pharma... |
| 17.01.2020 | Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO | Peter Ciriello
→ Peter Ciriello has climbed to the upper echelons of the French medical device maker Vygon Group. He will run the company’s US operations from the company’s headquarters in Pennsylvania and is also ta... |
| 04.10.2019 | Atlas-backed Dyne taps Joshua Brumm as CEO; Sekar Kathiresan woos cardiologist to gene editing startup | → Romesh Subramanian’s new biotech startup, Dyne Therapeutics, which is using oligonucleotides to degrade RNA responsible for disease has brought on Joshua Brumm as president and CEO. Subramanian will now take on the CSO... |
| 05.04.2019 | Investors Share Their Most Cringe-Worthy Misses: Term Sheet for Friday, April 5 | BIG REGRETS
On the eve of Lyft’s IPO, Twitter lit up with investors lamenting their failure to invest during the early days of the ride-hailing company.
Paid Content You can't secure what you can't see From ExtraHop
Upfront Ventures’ Mark S... |
| 05.04.2019 | Dyne Therapeutics nabs $50M | Dyne Therapeutics, a clinical-stage biotech startup focused on providing therapy to patients with muscle diseases, has launched with a $50 million Series A from Atlas Venture, Forbion and MPM Capital. Founded by Atlas, the Boston-area compa... |
| 03.04.2019 | Dyne Therapeutics Raises $50M in Series A Funding | Dyne Therapeutics, a Cambridge, Mass.-based new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, raised $50m in Series A funding.
Atlas Venture, which founded seeded and incubated the company, w... |
| 03.04.2019 | Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases | - |
| 03.04.2019 | Dyne Therapeutics Launches with $50M Series A |
CAMBRIDGE, MA, New biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 million Series A.
>> Click here for more funding data on Dyne Therapeutics
>> To exp... |
| 03.04.2019 | Dyne Therapeutics Launches with $50 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 million Series A. Atlas Venture founded, seeded and incubat... |
